Master of Biotechnology program (MBP) student Anita Huang looks back on her six-month internship at UCB in the United Kingdom and what she learned from the experience. In 2019, two students in ...

The current discussion of downstream bottlenecks arises from the ease with which up-stream activities generate protein and the desire for downstream operations to match upstream productivity. “In ...

Biopharmaceutical downstream processing requires precise control of multiple unit operations—from chromatography and filtration to viral inactivation—to ensure product quality and therapeutic efficacy ...

Upstream titers of 3–5 g/L, and up to 10–13 g/L, are outpacing downstream capacity, creating chromatography, filtration, and UF/DF throughput bottlenecks that elevate cost and delay timelines. Complex ...

Launching at the Festival of Biologics, ShunzymeX is designed to streamline process development and accelerate GMP readiness for complex biologics. TEESSIDE, England--(BUSINESS WIRE)--FUJIFILM ...

With the recent FDA approval of the CAR T-cell therapies Kymriah ® from Novartis and Yescarta ® from Kite Pharma, there has been a renewed interest in bioprocessing and the manufacturing facilities ...

Discover how Avantor’s global innovation centers help biopharma teams shorten timelines through expert-guided resin and buffer selection, downstream process development optimization, hands-on support ...

As a business owner or operations manager responsible for production, understanding the supply chain is essential to the success of your business. Any obstacle or impediment to the smooth flow of ...

Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...